Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds

Article abstract of DOI:10.1016/S0960-894X(98)00058-4

A 4-centre PDE 4 pharmacophore search has been carried out in several 3D-databases containing compounds belonging to different therapeutic areas. Losartan, an angiotensin-II antagonist, has been identified as a new lead compound for developing PDE 4 inhibitors. New families of compounds derived from losartan has been synthesized and their PDE inhibition has been measured.